NO20042056L - Farmasoytisk sammensetning for anvendelse ved behandling av malignanser som innbefatter en kombinasjon av et bisfosfonat, en COX-2 inhibitor og et taksol - Google Patents

Farmasoytisk sammensetning for anvendelse ved behandling av malignanser som innbefatter en kombinasjon av et bisfosfonat, en COX-2 inhibitor og et taksol

Info

Publication number
NO20042056L
NO20042056L NO20042056A NO20042056A NO20042056L NO 20042056 L NO20042056 L NO 20042056L NO 20042056 A NO20042056 A NO 20042056A NO 20042056 A NO20042056 A NO 20042056A NO 20042056 L NO20042056 L NO 20042056L
Authority
NO
Norway
Prior art keywords
taxol
cox
inhibitor
treatment
pharmaceutical composition
Prior art date
Application number
NO20042056A
Other languages
English (en)
Norwegian (no)
Inventor
Jonathan Green
Allan Lipton
Lois Mary Witters
Original Assignee
Lois Mary Witters
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lois Mary Witters filed Critical Lois Mary Witters
Publication of NO20042056L publication Critical patent/NO20042056L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20042056A 2001-10-19 2004-05-18 Farmasoytisk sammensetning for anvendelse ved behandling av malignanser som innbefatter en kombinasjon av et bisfosfonat, en COX-2 inhibitor og et taksol NO20042056L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34592101P 2001-10-19 2001-10-19
PCT/EP2002/011696 WO2003035081A1 (fr) 2001-10-19 2002-10-18 Composition pharmaceutique servant a traiter des tumeurs malignes et comprenant une combinaison de biphosphonate, d'inhibiteur de cox-2 et de taxol

Publications (1)

Publication Number Publication Date
NO20042056L true NO20042056L (no) 2004-05-18

Family

ID=23357099

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20042056A NO20042056L (no) 2001-10-19 2004-05-18 Farmasoytisk sammensetning for anvendelse ved behandling av malignanser som innbefatter en kombinasjon av et bisfosfonat, en COX-2 inhibitor og et taksol

Country Status (26)

Country Link
US (1) US7345088B2 (fr)
EP (1) EP1443942B1 (fr)
JP (1) JP2005506371A (fr)
KR (1) KR20040066103A (fr)
CN (1) CN100372539C (fr)
AT (1) ATE382347T1 (fr)
AU (1) AU2002363089B2 (fr)
BR (1) BR0213410A (fr)
CA (1) CA2461085A1 (fr)
CO (1) CO5570672A2 (fr)
DE (1) DE60224429T2 (fr)
DK (1) DK1443942T3 (fr)
EC (1) ECSP045054A (fr)
ES (1) ES2301710T3 (fr)
HK (1) HK1080733A1 (fr)
HU (1) HUP0402061A3 (fr)
IL (2) IL161090A0 (fr)
MX (1) MXPA04003671A (fr)
NO (1) NO20042056L (fr)
NZ (1) NZ532282A (fr)
PL (1) PL367707A1 (fr)
PT (1) PT1443942E (fr)
RU (1) RU2317819C2 (fr)
SI (1) SI1443942T1 (fr)
WO (1) WO2003035081A1 (fr)
ZA (1) ZA200402089B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0204756D0 (en) * 2002-02-28 2002-04-17 Novartis Ag Organic compounds
GB0328040D0 (en) * 2003-12-03 2004-01-07 Coleman Robert E Pharmaceutical uses of bisphosphonates
FR2939314A1 (fr) * 2008-12-04 2010-06-11 Univ Victor Segalen Bordeaux 2 Nouvelles compositions et methodes pour la potentialisation des signaux d'apoptose dans les cellules tumorales
PT2459176T (pt) 2009-07-31 2017-12-11 Gruenenthal Gmbh Método de cristalização e biodisponibilidade
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
WO2012071517A2 (fr) 2010-11-24 2012-05-31 Thar Pharmaceuticals, Inc. Nouvelles formes cristallines
US10195218B2 (en) 2016-05-31 2019-02-05 Grunenthal Gmbh Crystallization method and bioavailability

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1187130A (zh) * 1995-06-06 1998-07-08 麦克公司 用二磷酸盐预防与免疫抑制疗法有关的骨损失
CN1346282A (zh) * 1998-12-23 2002-04-24 G.D.西尔公司 在肿瘤的治疗中使用环加氧酶－2－抑制剂与一种或多种抗肿瘤剂作为联合治疗的方法
WO2001054688A1 (fr) * 2000-01-28 2001-08-02 Merck & Co., Inc. Traitement ou prevention du cancer de la prostate avec un medicament inhibiteur selectif de cox-2

Also Published As

Publication number Publication date
AU2002363089B2 (en) 2006-02-16
CN1703226A (zh) 2005-11-30
ATE382347T1 (de) 2008-01-15
NZ532282A (en) 2006-02-24
RU2004115337A (ru) 2005-04-20
RU2317819C2 (ru) 2008-02-27
US20050014726A1 (en) 2005-01-20
ECSP045054A (es) 2004-05-28
ES2301710T3 (es) 2008-07-01
JP2005506371A (ja) 2005-03-03
HUP0402061A2 (hu) 2005-02-28
MXPA04003671A (es) 2005-06-20
CA2461085A1 (fr) 2003-05-01
KR20040066103A (ko) 2004-07-23
US7345088B2 (en) 2008-03-18
SI1443942T1 (sl) 2008-08-31
HUP0402061A3 (en) 2007-05-29
IL161090A0 (en) 2004-08-31
DE60224429D1 (de) 2008-02-14
HK1080733A1 (en) 2006-05-04
WO2003035081A1 (fr) 2003-05-01
PT1443942E (pt) 2008-04-07
ZA200402089B (en) 2005-06-22
DE60224429T2 (de) 2008-12-18
IL161090A (en) 2010-04-15
EP1443942B1 (fr) 2008-01-02
CN100372539C (zh) 2008-03-05
EP1443942A1 (fr) 2004-08-11
BR0213410A (pt) 2004-11-03
PL367707A1 (en) 2005-03-07
DK1443942T3 (da) 2008-05-19
CO5570672A2 (es) 2005-10-31

Similar Documents

Publication Publication Date Title
HK1080733A1 (en) Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, a cox-2 inhibitor and a taxol
NO20034549L (no) Behandling av type 2 diabetes med inhibitorer av dipeptidyl peptidase IV
ATE366112T1 (de) Verwendung von zoledronsäure zur schmerzbehandlung
NO20063373L (no) CD40-antistoff-formuleringer og fremgangsmater
DK1373215T3 (da) Gelanamycinderivater egnet til behandling af cancer
BR0116370A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar em um paciente.
BR0307522A (pt) Utilização de um inibidor de lipoxigenase-15 para a manufatura de um medicamento, métodos para tratamento e prevenção e kit para o diagnóstico de predisposição à perda óssea
BR0316458A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto
BR0314081A (pt) Terapia de combinação compreendendo um bisfosfonato e um inibidor de hmg-coa redutase
BR0313081A (pt) Combinação de um inibidor de aromatase com um bisfosfanato
GB0020504D0 (en) Therapeutic method
HUP0301276A2 (hu) Kombinációs terápia ösztrogénérzékeny betegségek kezelésére
SE0004827D0 (sv) Therapeutic compounds
BR0315374A (pt) Compostos orgânicos
DE69924385D1 (de) Verwendung von angiotensin zur behandlung von krebsmetastasierung
ATE392213T1 (de) Verwendung von gamma-gt inhibitoren zur behandlung von chronischen degenerativerkrankungen
BR0315376A (pt) Combinações de benzotiadiazóis e inibidores de cox-2 para o tratamento de dor
BR0308105A (pt) Composição farmacêutica compreendendo um bisfosfonato e um inibidor de cox-2 para o tratamento de doenças de ossos
TW200519078A (en) 2-alkylidene-19-nor-vitamin d derivatives for the treatment of a second hip fracture
UA36041A (uk) Спосіб лікування хронічного панкреатиту, ускладненого псевдокістою
EA200600987A1 (ru) Применение сирамезина в лечении злокачественных опухолей
NO20051879L (no) Anvendelse av proteintyrosinfosfataseinhibitorer til forhindring og/eller behandling av kreft

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application